Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407028 · ClinicalTrials.gov registry record · Phase 2
Hyperbaric Oxygen Brain Injury Treatment Trial
A Phase 2 study of Traumatic Brain Injury, sponsored by Gaylan Rockswold.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 11
- Study locations
NCT02407028 is a Phase 2 study of Traumatic Brain Injury that is actively recruiting participants, run by Gaylan Rockswold. The registered enrollment target is 200 participants, below the 276-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT02407028, a Phase 2 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by Gaylan Rockswold.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.
Conditions Studied
Interventions
- DRUG Hyperbaric oxygen (1.5 ATA, no NBH)
- DRUG Hyperbaric oxygen (2.0 ATA, no NBH)
- DRUG Hyperbaric oxygen (2.5 ATA, no NBH)
- DRUG Hyperbaric oxygen (1.5 ATA + NBH)
- DRUG Hyperbaric oxygen (2.0 ATA + NBH)
Study Locations (11)
California
- UCSD Medical Center - Hillcrest Hospital - San Diego
Florida
- St. Mary's Medical Center - West Palm Beach
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kentucky
- University of Kentucky Hospital - Lexington
Maryland
- University of Maryland - Baltimore
Michigan
- Detroit Receiving Hospital - Detroit
Minnesota
- Hennepin County Hospital - Minneapolis
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407028
The ClinicalTrials.gov registry entry for NCT02407028 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (28% lower). The listed sponsor is Gaylan Rockswold, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 5 interventions - of which Hyperbaric oxygen (1.5 ATA, no NBH) is the first listed.
NCT02407028 reports 11 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT02407028 about?
NCT02407028 is a clinical study titled "Hyperbaric Oxygen Brain Injury Treatment Trial". The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.
What is the current status of trial NCT02407028?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2018-06-25. Estimated completion is 2029-06-30.
What conditions does trial NCT02407028 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT02407028?
The interventions under investigation include: Hyperbaric oxygen (1.5 ATA, no NBH) (DRUG), Hyperbaric oxygen (2.0 ATA, no NBH) (DRUG), Hyperbaric oxygen (2.5 ATA, no NBH) (DRUG), Hyperbaric oxygen (1.5 ATA + NBH) (DRUG), Hyperbaric oxygen (2.0 ATA + NBH) (DRUG).
Who is sponsoring clinical trial NCT02407028?
This trial is sponsored by Gaylan Rockswold, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407028 being conducted?
This trial has 11 study locations across California, Florida, Iowa, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)
RECRUITING · Phase 2
-
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
RECRUITING · Phase 2
-
High Intensity Step Training After Traumatic Brain Injury
RECRUITING · Phase 2
-
Sildenafil for Microvasculopathy in Chronic TBI
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
RECRUITING · Phase 2
-
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.